EFFECT OF PHOSPHODIESTERASE 4 (PDE4) INHIBITORS ON EOTAXIN EXPRESSION IN HUMAN BRONCHIAL EPITHELIAL CELLS
暂无分享,去创建一个
[1] H. Liu,et al. Phosphodiesterase 3A expression is modulated by nitric oxide in rat pulmonary artery smooth muscle cells. , 2010, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[2] L. Petecchia,et al. A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro. , 2010, Pulmonary pharmacology & therapeutics.
[3] Y. Jong,et al. Suppressive effects of formoterol and salmeterol on eotaxin‐1 in bronchial epithelial cells , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[4] F. Martinez,et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.
[5] F. Martinez,et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.
[6] J. Vestbo,et al. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD , 2009, European Respiratory Journal.
[7] D. Mokra,et al. Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[8] D. Spina,et al. PDE4 inhibitors: current status , 2008, British journal of pharmacology.
[9] D. Cabrol,et al. The PDE4 Inhibitor Rolipram Prevents NF-κB Binding Activity and Proinflammatory Cytokine Release in Human Chorionic Cells1 , 2008, The Journal of Immunology.
[10] J. Phillips,et al. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. , 2007, European journal of pharmacology.
[11] L. Fabbri,et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[12] Y. Aragane,et al. Antagonism of IL-4 Signaling by a Phosphodiesterase-4 Inhibitor, Rolipram, in Human T Cells , 2007, International Archives of Allergy and Immunology.
[13] M. Rahman,et al. IL-17A Induces Eotaxin-1/CC Chemokine Ligand 11 Expression in Human Airway Smooth Muscle Cells: Role of MAPK (Erk1/2, JNK, and p38) Pathways1 , 2006, The Journal of Immunology.
[14] G. Hoser,et al. Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[15] T. Kasahara,et al. Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast. , 2006, Biological & pharmaceutical bulletin.
[16] M. Strek,et al. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. , 2006, Chest.
[17] H. Cheon,et al. Roflumilast Inhibits Lipopolysaccharide-Induced Inflammatory Mediators via Suppression of Nuclear Factor-κB, p38 Mitogen-Activated Protein Kinase, and c-Jun NH2-Terminal Kinase Activation , 2005, Journal of Pharmacology and Experimental Therapeutics.
[18] Kam Y. J. Zhang,et al. Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.
[19] E. Bateman,et al. Roflumilast—An oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial: The Lancet 2005;366(9485):563–71. , 2005 .
[20] E. Bateman,et al. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial , 2005, The Lancet.
[21] J. Cortijo,et al. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. , 2005, Pharmacology & therapeutics.
[22] C. Page,et al. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. , 2005, Pulmonary pharmacology & therapeutics.
[23] K. Rabe,et al. Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. , 2005, The Journal of allergy and clinical immunology.
[24] Y. Hamasaki,et al. Regulatory mechanisms of Th2 cytokine-induced eotaxin-3 production in bronchial epithelial cells: possible role of interleukin 4 receptor and nuclear factor-kappaB. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[25] P. Peachell,et al. Effects of phosphodiesterase inhibitors on interleukin‐4 and interleukin‐13 generation from human basophils , 2004, British journal of pharmacology.
[26] S. Mackenzie,et al. The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma , 2004, Respiratory research.
[27] Chang Xu,et al. Beta2-integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and beta2-adrenoceptor activation in human eosinophils. , 2004, Pulmonary pharmacology & therapeutics.
[28] G. Verleden,et al. Modulation by cAMP of IL‐1β‐induced eotaxin and MCP‐1 expression and release in human airway smooth muscle cells , 2003, European Respiratory Journal.
[29] K. Ohta,et al. Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells. , 2003, Cellular immunology.
[30] C. E. Hudson,et al. Regulatory Effects of Eotaxin, Eotaxin-2, and Eotaxin-3 on Eosinophil Degranulation and Superoxide Anion Generation1 , 2002, Experimental biology and medicine.
[31] T. Williams,et al. Regulation of human eotaxin-3/CCL26 expression: modulation by cytokines and glucocorticoids. , 2002, Cytokine.
[32] S. Rankin,et al. Eotaxin-2 Generation Is Differentially Regulated by Lipopolysaccharide and IL-4 in Monocytes and Macrophages1 , 2002, The Journal of Immunology.
[33] D M Essayan,et al. Cyclic nucleotide phosphodiesterases. , 2001, The Journal of allergy and clinical immunology.
[34] V. Lagente,et al. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme , 2001, British journal of pharmacology.
[35] R. Breuer,et al. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. , 2001, American journal of respiratory cell and molecular biology.
[36] E. Israel,et al. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. , 2001, American journal of respiratory and critical care medicine.
[37] T. Williams,et al. Eotaxin and the attraction of eosinophils to the asthmatic lung , 2001, Respiratory research.
[38] A. Knox,et al. Regulation of TNF‐α‐induced eotaxin release from cultured human airway smooth muscle cells by β2‐agonists and corticosteroids , 2001 .
[39] P. Askenase,et al. Basophil Responses to Chemokines Are Regulated by Both Sequential and Cooperative Receptor Signaling1 , 2000, The Journal of Immunology.
[40] V. Casolaro,et al. Activation of Eotaxin Gene Transcription by NF-κB and STAT6 in Human Airway Epithelial Cells , 1999, The Journal of Immunology.
[41] J. White,et al. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. , 1999, Journal of immunology.
[42] J. Hurley. Structure, Mechanism, and Regulation of Mammalian Adenylyl Cyclase* , 1999, The Journal of Biological Chemistry.
[43] P. Barnes,et al. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. , 1999, American journal of respiratory cell and molecular biology.
[44] A. Bellini,et al. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation , 1998, Clinical and experimental immunology.
[45] I. Adcock,et al. Phosphodiesterase expression in human epithelial cells. , 1998, The American journal of physiology.
[46] T. Torphy. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.
[47] J. Beleta,et al. Inhibition of eotaxin‐mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram , 1997, British journal of pharmacology.
[48] J. Drazen,et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. , 1997, The Journal of clinical investigation.
[49] C. Hirshman,et al. TNF-alpha inhibits isoproterenol-stimulated adenylyl cyclase activity in cultured airway smooth muscle cells. , 1997, The American journal of physiology.
[50] J. Demartino,et al. Cloning, expression, and characterization of the human eosinophil eotaxin receptor , 1996, The Journal of experimental medicine.
[51] S. Morris,et al. TNF modulates endothelial properties by decreasing cAMP. , 1995, The American journal of physiology.
[52] E. Aandahl,et al. Localized effects of cAMP mediated by distinct routes of protein kinase A. , 2004, Physiological reviews.
[53] A. Knox,et al. Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[54] V. Casolaro,et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. , 2001, American journal of respiratory cell and molecular biology.
[55] Y. Kato,et al. Chemokine production by the BEAS-2B human bronchial epithelial cells: differential regulation of eotaxin, IL-8, and RANTES by TH2- and TH1-derived cytokines. , 2000, The Journal of allergy and clinical immunology.